Mengis Capital Management buys $2,117,606 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Mengis Capital Management scooped up 11,900 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 33,280 shares of Merck & Co. which is valued at $2,117,606.Merck & Co. makes up approximately 1.79% of Mengis Capital Management’s portfolio.

Other Hedge Funds, Including , Linscomb Williams boosted its stake in MRK in the latest quarter, The investment management firm added 2,511 additional shares and now holds a total of 58,191 shares of Merck & Co. which is valued at $3,716,077. Merck & Co. makes up approx 0.37% of Linscomb Williams’s portfolio. Valicenti Advisory Services Inc added MRK to its portfolio by purchasing 3,531 company shares during the most recent quarter which is valued at $206,917. Merck & Co. makes up approx 0.13% of Valicenti Advisory Services Inc’s portfolio.Eqis Capital Management reduced its stake in MRK by selling 113 shares or 0.73% in the most recent quarter. The Hedge Fund company now holds 15,441 shares of MRK which is valued at $911,328. Merck & Co. makes up approx 0.06% of Eqis Capital Management’s portfolio.Partnerre Asset Management Corp reduced its stake in MRK by selling 100 shares or 0.53% in the most recent quarter. The Hedge Fund company now holds 18,776 shares of MRK which is valued at $1,108,160. Merck & Co. makes up approx 0.56% of Partnerre Asset Management Corp’s portfolio.

Merck & Co. closed down -0.03 points or -0.05% at $63.32 with 66,50,069 shares getting traded on Monday. Post opening the session at $63.35, the shares hit an intraday low of $63.21 and an intraday high of $63.75 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.

Many Wall Street Analysts have commented on Merck & Co.. Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.Company shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold”, Firm has raised the Price Target to $ 59 from a previous price target of $58 .

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.